Eisai Company, Ltd. Announces Agreement To License Novel Adjuvant From Sanofi Pasteur
LYON, France, Oct. 31 /PRNewswire/ -- Sanofi pasteur, the vaccines business of the sanofi-aventis Group , has entered into an agreement with Eisai Co., Ltd. to license their novel adjuvant, E6020, for use in the development of new vaccines to treat or prevent human illnesses. E6020 is a chemically synthesized adjuvant that will be tested by sanofi pasteur to determine its ability to enhance the immune response to a broad range of vaccines.
Under the terms of the agreement, Eisai will provide a license to sanofi pasteur to incorporate the E6020 adjuvant for use in vaccines throughout all geographical regions. In return Eisai will receive upfront payments, milestone payments, and royalty payments on product sales. Sanofi pasteur will commercialize the adjuvanted vaccines developed in this collaboration. Further financial details of the agreement are not disclosed.
This contract is part of sanofi pasteur's ongoing corporate commitment to protect and improve human health worldwide by providing superior, innovative vaccines for the prevention and treatment of disease.
The sanofi-aventis Group is the world's third-largest pharmaceutical company, ranking number one in Europe. Backed by a world-class R&D organization, sanofi-aventis is developing leading positions in seven major therapeutic areas: cardiovascular disease, thrombosis, oncology, metabolic diseases, central nervous system, internal medicine, and vaccines. The sanofi-aventis Group is listed in Paris and in New York .
Sanofi pasteur, the vaccines business of the sanofi-aventis Group, sold nearly a billion doses of vaccine in 2004, making it possible to protect more than 500 million people across the globe, which is about 1.4 million per day. The company offers the broadest range of vaccines, providing protection against 20 bacterial and viral diseases. For more information, please visit: http://www.sanofipasteur.com
Forward Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. These statements include financial projections and estimates and their underlying assumptions, statements regarding plans, objectives and expectations with respect to future operations, products and services, and statements regarding future performance. Forward-looking statements are generally identified by the words "expect," "anticipates," "believes," "intends," "estimates," "plans" and similar expressions. Although sanofi-aventis' management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of sanofi-aventis, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the public filings with the SEC and the AMF made by sanofi-aventis, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward- Looking Statements" in sanofi-aventis' annual report on Form 20-F for the year ended December 31, 2004. Other than as required by applicable law, sanofi- aventis does not undertake any obligation to update or revise any forward- looking information or statements.
Sanofi-aventis Group subsidiaries in the United States include Sanofi- Synthelabo Inc., Aventis Pharmaceuticals Inc. and Sanofi Pasteur Inc.
sanofi pasteur sanofi pasteur Alain BERNAL Len LAVENDA Vice-President Corporate Communications U.S. Media Relations Tel: + 33-(0)4-37-37-78-97 Tel: +1-570-839-4446 Fax: +33-(0)4-37-37-77 89 Len.Lavenda@sanofipasteur.comSanofi pasteur
CONTACT: Alain Bernal, Vice-President Corporate Communications, Tel:+33-(0)4-37-37-78-97, Fax: +33-(0)4-37-37-77-89; or sanofi pasteur, LenLavenda, U.S. Media Relations, Tel: +1-570-839-4446,Len.Lavenda@sanofipasteur.com, both of Sanofi pasteur
Web site: http://www.sanofipasteur.com/